Viewing Study NCT05374928


Ignite Creation Date: 2025-12-26 @ 10:34 AM
Ignite Modification Date: 2025-12-31 @ 6:59 PM
Study NCT ID: NCT05374928
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-04
First Post: 2022-05-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Human Epilepsy Project 3
Sponsor: NYU Langone Health
Organization:

Study Overview

Official Title: Human Epilepsy Project 3: Newly Diagnosed Idiopathic Generalized Epilepsy
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: HEP3
Brief Summary: By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to make more informed decisions about the factors affecting their quality of life, including plans for driving, relationships, pregnancy, schooling, work, and play. In addition to its impact on clinical care, the data and specimens collected in HEP3, including sequential electrophysiology, biochemical profiles and neuroimaging and banked DNA for future genomics studies, have the potential to provide new insights into the biological basis of IGE, thereby advancing the discovery of effective treatments and cures. By enrolling both newly diagnosed subjects (prognosis unknown) as well as subjects with established IGE who are already determined to be treatment resistant or treatment responsive, the study team can immediately test potential biomarkers in a confirmation cohort, which will accelerate identification of predictive biomarkers.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: